AGTR1 and COVID-19: On this basis, it has been hypothesized that the use of ACE inhibitors and AT1R blockers in the treatment of arterial hypertension during the COVID-19 pandemic may make the patient more susceptible to SARS-CoV-2 infection, and the course of COVID-19 may be more severe.